333 related articles for article (PubMed ID: 29032374)
21. ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) does not affect proliferation, apoptosis, or angiogenesis as compared to standard liver resection for colorectal liver metastases.
Joechle K; Moser C; Ruemmele P; Schmidt KM; Werner JM; Geissler EK; Schlitt HJ; Lang SA
World J Surg Oncol; 2017 Mar; 15(1):57. PubMed ID: 28270160
[TBL] [Abstract][Full Text] [Related]
22. Associating liver partition and portal vein ligation for staged hepatectomy offers high oncological feasibility with adequate patient safety: a prospective study at a single center.
Alvarez FA; Ardiles V; de Santibañes M; Pekolj J; de Santibañes E
Ann Surg; 2015 Apr; 261(4):723-32. PubMed ID: 25493362
[TBL] [Abstract][Full Text] [Related]
23. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
24. Two-Stage Hepatectomy and ALPPS for Advanced Bilateral Liver Metastases: a Tailored Approach Balancing Risk and Outcome.
Baumgart J; Jungmann F; Bartsch F; Kloth M; Mittler J; Heinrich S; Lang H
J Gastrointest Surg; 2019 Dec; 23(12):2391-2400. PubMed ID: 30820795
[TBL] [Abstract][Full Text] [Related]
25. Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?
Rhaiem R; Duramé A; Primavesi F; Dorcaratto D; Syn N; Rodríguez ÁH; Dupré A; Piardi T; Fernández GB; Villaverde AP; Rodríguez Sanjuán JC; Santiago RF; Fernández-Moreno MC; Ferret G; Ben SL; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E; Kianmanesh R; Di Martino M
Surgery; 2024 Jul; 176(1):124-133. PubMed ID: 38519408
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
27. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
[TBL] [Abstract][Full Text] [Related]
28. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Buettner S; Amini N; Pawlik TM
J Surg Oncol; 2016 Sep; 114(3):361-7. PubMed ID: 27264476
[TBL] [Abstract][Full Text] [Related]
29. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
[TBL] [Abstract][Full Text] [Related]
30. Associating Liver Partition and Portal vein ligation for Staged hepatectomy after pre-operative chemotherapy.
Vondran FWR; Oldhafer F; Ringe KI; Wirth TC; Kleine M; Jäger MD; Klempnauer J; Bektas H
ANZ J Surg; 2018 Apr; 88(4):E324-E328. PubMed ID: 28419692
[TBL] [Abstract][Full Text] [Related]
31. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
[TBL] [Abstract][Full Text] [Related]
33. ALPPS versus two-stage hepatectomy for colorectal liver metastases--a comparative retrospective cohort study.
Bednarsch J; Czigany Z; Sharmeen S; van der Kroft G; Strnad P; Ulmer TF; Isfort P; Bruners P; Lurje G; Neumann UP
World J Surg Oncol; 2020 Jun; 18(1):140. PubMed ID: 32580729
[TBL] [Abstract][Full Text] [Related]
34. Scandinavian multicenter study on the safety and feasibility of the associating liver partition and portal vein ligation for staged hepatectomy procedure.
Røsok BI; Björnsson B; Sparrelid E; Hasselgren K; Pomianowska E; Gasslander T; Bjørnbeth BA; Isaksson B; Sandström P
Surgery; 2016 May; 159(5):1279-86. PubMed ID: 26606881
[TBL] [Abstract][Full Text] [Related]
35. Impact of split completeness on future liver remnant hypertrophy in associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in hepatocellular carcinoma: Complete-ALPPS versus partial-ALPPS.
Chan ACY; Chok K; Dai JWC; Lo CM
Surgery; 2017 Feb; 161(2):357-364. PubMed ID: 27596751
[TBL] [Abstract][Full Text] [Related]
36. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) procedure for colorectal liver metastasis.
Hernandez-Alejandro R; Ruffolo LI; Alikhanov R; Björnsson B; Torres OJM; Serrablo A
Int J Surg; 2020 Oct; 82S():103-108. PubMed ID: 32305531
[TBL] [Abstract][Full Text] [Related]
37. Characterization of early recurrences following liver resection by ALPPS and two stage hepatectomy in patients with colorectal liver-metastases and small future liver remnants; a translational substudy of the LIGRO-RCT.
Røsok BI; Høst-Brunsell T; Brudvik KW; Carling U; Dorenberg E; Björnsson B; Lothe RA; Bjørnbeth BA; Sandström P
HPB (Oxford); 2019 Aug; 21(8):1017-1023. PubMed ID: 30765198
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy is associated with better oncological outcomes after ALPPS for colorectal liver metastases.
Alvarez FA; Ardiles V; Chara C; de Santibañes M; Sánchez Clariá R; Pekolj J; de Santibañes E
Updates Surg; 2024 Jun; 76(3):855-868. PubMed ID: 38647857
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors differ according to KRAS mutational status: A classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis.
Moro A; Mehta R; Tsilimigras DI; Sahara K; Paredes AZ; Bagante F; Guglielmi A; Alexandrescu S; Poultsides GA; Sasaki K; Aucejo FN; Pawlik TM
Surgery; 2020 Sep; 168(3):497-503. PubMed ID: 32675031
[TBL] [Abstract][Full Text] [Related]
40. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
